FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004306483> ?p ?o ?g. }

• W2004306483 endingPage "208" @default.
• W2004306483 startingPage "202" @default.
• W2004306483 abstract "Acute myeloid leukaemia (AML) secondary to myelodysplastic syndrome (MDS) is characterized by poor prognosis, namely in older patients. The combination of fludarabine (F) with cytarabine (ARA-C) ± G-CSF was proven as effective in patients with poor risk AML. The efficacy and toxicity of a regimen including F + ARA-C as sequential continuous infusion (CI-FLA) in 64 untreated patients aged >60 years, in which AML arose after a previous MDS, was investigated. Median age was 67 years (61–81). In patients achieving CR, an additional course, followed by G-CSF to mobilize CD34+ cells and subsequent autologous stem cell transplantation (ASCT) were programmed. Overall, 43 patients (67%) achieved complete remission (CR). There were 10 induction deaths (16%), while 11 patients (17%) were refractory to induction treatment. Thirty-four patients (79% of remitters) were eligible for the consolidation and 30 were monitorized for the mobilization of CD34+ cells, collection being successful in 20 of them (67%). Median number of CD34+ cells/kg collected was 6.8 × 10E6. Thirteen patients (20% of the whole population) received ASCT. Median disease free survival (DFS) and overall survival (OS) were 10 and 9 months, respectively. Survival at 5 years is projected to 15%. The only parameter significantly related to either DFS duration or OS duration was unfavourable cytogenetics, which did significantly influence also CR achievement. CI-FLA is effective in elderly patients with AML secondary to previously diagnosed MDS. Best results are achievable in the subgroup of patients with diploid karyotype. Copyright © 2010 John Wiley & Sons, Ltd." @default.
• W2004306483 created "2016-06-24" @default.
• W2004306483 creator A5042609656 @default.
• W2004306483 creator A5058381643 @default.
• W2004306483 creator A5060752899 @default.
• W2004306483 creator A5079633362 @default.
• W2004306483 creator A5080989131 @default.
• W2004306483 date "2010-12-01" @default.
• W2004306483 modified "2023-10-14" @default.
• W2004306483 title "Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome" @default.
• W2004306483 cites W1492609361 @default.
• W2004306483 cites W1556454749 @default.
• W2004306483 cites W1925684361 @default.
• W2004306483 cites W1970925456 @default.
• W2004306483 cites W1972962779 @default.
• W2004306483 cites W1976698787 @default.
• W2004306483 cites W1978809616 @default.
• W2004306483 cites W1985586206 @default.
• W2004306483 cites W1991724464 @default.
• W2004306483 cites W1999072266 @default.
• W2004306483 cites W1999688002 @default.
• W2004306483 cites W2004902429 @default.
• W2004306483 cites W2011872304 @default.
• W2004306483 cites W2017069678 @default.
• W2004306483 cites W2026110163 @default.
• W2004306483 cites W2026571750 @default.
• W2004306483 cites W2031610234 @default.
• W2004306483 cites W2034058960 @default.
• W2004306483 cites W2046185040 @default.
• W2004306483 cites W2055409653 @default.
• W2004306483 cites W2066420284 @default.
• W2004306483 cites W2068780288 @default.
• W2004306483 cites W2077417004 @default.
• W2004306483 cites W2079694390 @default.
• W2004306483 cites W2088343293 @default.
• W2004306483 cites W2088965961 @default.
• W2004306483 cites W2097035477 @default.
• W2004306483 cites W2100934853 @default.
• W2004306483 cites W2103468550 @default.
• W2004306483 cites W2107398329 @default.
• W2004306483 cites W2109065151 @default.
• W2004306483 cites W2112332290 @default.
• W2004306483 cites W2113446668 @default.
• W2004306483 cites W2124289169 @default.
• W2004306483 cites W2129168184 @default.
• W2004306483 cites W2142896063 @default.
• W2004306483 cites W2144310977 @default.
• W2004306483 cites W2144749137 @default.
• W2004306483 cites W2158171581 @default.
• W2004306483 cites W2158338106 @default.
• W2004306483 cites W2162700652 @default.
• W2004306483 cites W2162920526 @default.
• W2004306483 cites W2166525128 @default.
• W2004306483 cites W4293241248 @default.
• W2004306483 cites W2147083172 @default.
• W2004306483 doi "https://doi.org/10.1002/hon.943" @default.
• W2004306483 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21136583" @default.
• W2004306483 hasPublicationYear "2010" @default.
• W2004306483 type Work @default.
• W2004306483 sameAs 2004306483 @default.
• W2004306483 citedByCount "8" @default.
• W2004306483 countsByYear W20043064832013 @default.
• W2004306483 countsByYear W20043064832016 @default.
• W2004306483 countsByYear W20043064832018 @default.
• W2004306483 countsByYear W20043064832019 @default.
• W2004306483 countsByYear W20043064832020 @default.
• W2004306483 crossrefType "journal-article" @default.
• W2004306483 hasAuthorship W2004306483A5042609656 @default.
• W2004306483 hasAuthorship W2004306483A5058381643 @default.
• W2004306483 hasAuthorship W2004306483A5060752899 @default.
• W2004306483 hasAuthorship W2004306483A5079633362 @default.
• W2004306483 hasAuthorship W2004306483A5080989131 @default.
• W2004306483 hasConcept C126322002 @default.
• W2004306483 hasConcept C141071460 @default.
• W2004306483 hasConcept C143998085 @default.
• W2004306483 hasConcept C2776694085 @default.
• W2004306483 hasConcept C2776755627 @default.
• W2004306483 hasConcept C2778041864 @default.
• W2004306483 hasConcept C2778729363 @default.
• W2004306483 hasConcept C2779263901 @default.
• W2004306483 hasConcept C2780007613 @default.
• W2004306483 hasConcept C2780817109 @default.
• W2004306483 hasConcept C2781413609 @default.
• W2004306483 hasConcept C2908647359 @default.
• W2004306483 hasConcept C2911091166 @default.
• W2004306483 hasConcept C71924100 @default.
• W2004306483 hasConcept C90924648 @default.
• W2004306483 hasConcept C99454951 @default.
• W2004306483 hasConceptScore W2004306483C126322002 @default.
• W2004306483 hasConceptScore W2004306483C141071460 @default.
• W2004306483 hasConceptScore W2004306483C143998085 @default.
• W2004306483 hasConceptScore W2004306483C2776694085 @default.
• W2004306483 hasConceptScore W2004306483C2776755627 @default.
• W2004306483 hasConceptScore W2004306483C2778041864 @default.
• W2004306483 hasConceptScore W2004306483C2778729363 @default.
• W2004306483 hasConceptScore W2004306483C2779263901 @default.
• W2004306483 hasConceptScore W2004306483C2780007613 @default.
• W2004306483 hasConceptScore W2004306483C2780817109 @default.

• next